Compare Sherwin-Williams Company (The) Common Stock (SHW) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sherwin-Williams Company (The) Common Stock vs Summit Therapeutics Inc — how do they compare? Sherwin-Williams Company (The) Common Stock trades at $326.76 (market cap $78.68B), while Summit Therapeutics Inc trades at $15.03 (market cap $12.38B). The key difference: Sherwin-Williams Company (The) Common Stock is far larger — about 6.4× Summit Therapeutics Inc's market cap, and Sherwin-Williams Company (The) Common Stock pays a 0.99% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SHW | SMMT | |
|---|---|---|
Market Cap | $78.68B | $12.38B |
Volume | 1,245,324 | 7,111,626 |
Sector | Basic Materials | Health |
52-Week High | $372.60 | $26.38 |
52-Week Low | $293.00 | $12.43 |
Enterprise Value | $92.60B | $11.71B |
Dividend Yield | 0.99% | — |
Typical Hold Time | — | 16 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sherwin-Williams (SHW) trades at $324.10, up 1.21% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals but maintains robust fundamentals with 65.12% ROE and expanding manufacturing capacity. Recent facility expansions in Statesville enhance production capabilities, positioning the company for continued market share gains.
Outlook remains positive with analyst consensus at Buy (57.9%) and $383.64 price target, though high valuation multiples (P/E 29.9) and competitive pressures present risks. Earnings growth and strategic investments support upside potential, while margin compression and economic sensitivity warrant monitoring.
Summit Therapeutics (SMMT) trades at $15.52, down 9.4% today but remains volatile following recent positive developments. The stock shows a bullish technical signal with strong moving average support and neutral oscillators. Fundamentally, the company reports no revenue and significant losses (-$1.08B net income for 2025), but recent news includes a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, driving investor optimism.
The outlook is cautiously optimistic due to strong analyst support (65% buy ratings) and a $29.33 consensus price target, representing significant upside. Key risks include ongoing cash burn, lack of current revenue, and clinical trial execution. The AstraZeneca partnership provides substantial validation and funding, but investors should monitor upcoming Q3 2026 earnings and clinical milestones for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sherwin-Williams Company (The) Common Stock
The Sherwin-Williams Company manufactures, develops, and distributes paints, coatings, and related products through three segments: Paint Stores Group, operating more than 4,900 company-owned stores selling Sherwin-Williams-branded products; Consumer Brands Group, selling brands such as Valspar, Dutch Boy, Krylon, and Minwax through mass merchandisers and home centers; and Performance Coatings Group, supplying industrial, construction, and transportation coatings in more than 120 countries.
Read more on SHW →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
